Abstracts Archive - Page 112 of 2425 - ACR Meeting Abstracts

Abstract Number: 1315 • ACR Convergence 2024
From Presentation to Publication: Tracking the Publication Rate of Abstracts Presented at American College of Rheumatology Convergence Conference in the Years 2015 and 2018
Shreena Kamlesh Gandhi¹, Shivani Patel², Saransh Narang³, Aayushi Rajani³ and Kaleb Michaud⁴, ¹KU School of Medicine, Wichita, Wichita, KS, ²Washington University in St. Louis, St. Louis, MO, ³Medical College, Baroda, Baroda, India, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The ACR Convergence meeting attracts rheumatology researchers worldwide to present their peer- reviewed abstracts for a global audience either as a poster or oral…
Abstract Number: 1329 • ACR Convergence 2024
Investigating Predictors of Transfusion in Rheumatoid Arthritis and Osteoarthritis Patients Undergoing Knee Arthroplasty
Stephen Batter¹, Huong Do¹, Dongmei Sun², Ahmed Deeb¹, Trang Bui¹, Jason Blevins¹, Mark Figgie¹, Gwo-Chin Lee¹, J. Alex B. Gibbons³, Bella Mehta⁴, Susan Goodman⁵ and Linda A Russell¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Birmingham, AL, ³Columbia University Vagelos College of Physicians & Surgeons, New York, NY, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, New York 10025, NY
Background/Purpose: Use of ambulatory surgery in arthroplasty is increasing, but the need for transfusion mandates hospital admission. Despite the significant drop in transfusion rate linked…
Abstract Number: 1339 • ACR Convergence 2024
When Medications Fail: A Mixed Methods Study Evaluating the Experience and Health-Related Quality of Life (HRQOL) of Adults with Rheumatoid Arthritis Non-Responsive to Treatment
Kathleen Carluzzo¹, Erin Knight¹, Sidney May¹, Laura Bernstein², Kristen Mueller³, Clifton Bingham⁴ and Karen Schifferdecker¹, ¹Dartmouth College, Lebanon, NH, ²Dartmouth College, Philadelphia, PA, ³Arthritis Foundation, Washington, DC, ⁴Johns Hopkins University, Baltimore, MD
Background/Purpose: RA treatment involves an iterative approach to identifying effective medications for patients. While response varies, there is little in-depth understanding of patients’ perspectives of…
Abstract Number: 1287 • ACR Convergence 2024
Development of the Academy for Workforce Advancement to Enrich Rheumatology Diversity
Eli Miloslavsky¹, Greta Sirek², Mia Chandler³, Renato Ferrandiz⁴, Grace Wright⁵, Maura Iversen⁶, Daniel Solomon², Jeffrey Katz², Ellen Gravallese⁷, Sciaska Ulysse⁸, Valerie Stone², Gail Kerr⁹ and Candace Feldman², ¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Boston Children’s Hospital, Boston, MA, ⁴North Alabama Medical Center, Florence, AL, ⁵AWIR, New York, NY, ⁶Johnson & Wales University, Boston, MA, ⁷Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA, ⁸University of California San Francisco, School of Medicine, San Francisco, CA, ⁹Washington DC VAMC/Georgetown and Howard Universities, Washington, DC
Background/Purpose: Workforce diversity enhances scientific inquiry and improves healthcare access and quality of care for minoritized populations. While other medicine subspecialties have increasing numbers of…
Abstract Number: 1368 • ACR Convergence 2024
Do CsDMARDs Still Play a Significant Role in Managing Rheumatoid Arthritis in the Current Biologic/JAKI Era? A Prospective Observational Study to Estimate the Extent of Response to Conventional Synthetic DMARDs in RA– Experience from a Tertiary Care Center in South India
Prabhu Vasanth¹, John Mathew² and Divya K³, ¹Christian Medical college , Vellore , India, Vellore, Tamil Nadu, India, ²Christian Medical college , Vellore , India, Vellore, India, ³Christian Medical College, Vellore, Tamil Nadu, India
Background/Purpose: Conventional synthetic DMARDs remained the mainstay of treatment of RA for decades. However, their use has decreased recently due to the emergence of biological…
Abstract Number: 1328 • ACR Convergence 2024
Carpal Tunnel Syndrome Is an Early Unrecognized Feature of Rheumatoid Arthritis: A Population-Based Study
Roslin Jose George¹, Noah Frechette¹, Iqra Javed¹, Bradly Kimbrough², Sara Achenbach³, Elena Joerns¹, Vanessa Kronzer¹, John Davis¹, Cynthia Crowson¹ and Elena Myasoedova¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic Rochester, Rochester, MN, ³Mayo Clinic, Rochester, Rochester, MN
Background/Purpose: Carpal tunnel syndrome (CTS) is a common complication of rheumatoid arthritis (RA). However, the occurrence of CTS before RA and the effect of RA…
Abstract Number: 1333 • ACR Convergence 2024
Deciphering Variation in Real-World Early RA Outcomes: A Longitudinal Analysis of the Canadian Early Arthritis Cohort (CATCH) Study
Orit Schieir¹, Marie-France Valois², Gilles Boire³, Louis Bessette⁴, Carter Thorne⁵, Susan Bartlett², Glen Hazlewood⁶, Carol Hitchon⁷, Diane Tin⁵, Hugues Allard-Chamard⁸, Bindee Kuriya⁹, Janet Pope¹⁰ and Vivian Bykerk¹¹, and on behalf of CATCH Investigators, ¹McGill University, Montreal, QC, Canada, ²Centre for Outcomes Research & Eval, Montreal, QC, Canada, ³Retired, Sherbrooke, QC, Canada, ⁴University of Laval, Quebec City, QC, Canada, ⁵Newmarket Rheumatology Consultants, Newmarket, ON, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸University of Sherbrooke, Sherbrooke, QC, Canada, ⁹University of Toronto, Toronto, Canada, ¹⁰University of Western Ontario, London, ON, Canada, ¹¹Hospital For Special Surgery, New York, NY
Background/Purpose: Despite advances in early RA diagnosis and therapies, treatment outcomes can still vary considerably. Our objective was to compare short and long-term disease control…
Abstract Number: 1370 • ACR Convergence 2024
Upadacitinib vs TNFi and Other JAKi Treatment Outcomes in Australian Rheumatoid Arthritis Patients: Descriptive Comparison of Persistence and Effectiveness Using the OPAL Dataset
Sabina Ciciriello¹, Peter Youssef², Talib Tahir³, Tegan Smith⁴, Catherine O'Sullivan⁴, Joanna Leadbetter⁵, Belinda Butcher⁵, Miriam Calao⁶, Nicole Walsh⁶ and Geoffrey Littlejohn⁷, ¹The University of Melbourne, Melbourne, Victoria, Australia, ²Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia, ³Coburg Rheumatology Service, Coburg, Victoria, Australia, ⁴OPAL Rheumatology Ltd, Geelong, Victoria, Australia, ⁵WriteSource Medical Pty Ltd, Lane Cove, New South Wales, Australia, ⁶AbbVie Pty Ltd, Mascot, New South Wales, Australia, ⁷Monash University, Clayton, Victoria, Australia
Background/Purpose: To descriptively compare treatment patterns, persistence and effectiveness of upadacitinib (UPA), other JAK inhibitors (JAKi) and tumour necrosis factor inhibitors (TNFi) in rheumatoid arthritis…
Abstract Number: 1289 • ACR Convergence 2024
Gout Education for Primary Care Providers: A Scoping Review
Madeline O’Sullivan¹, Michael Battistone², Gary Kunkel³, Kalani Raphael¹, Lydia Howes⁴, Naomi Schlesinger¹ and Andrea Barker², ¹University of Utah, Salt Lake City, UT, ²Salt Lake City VA, Salt Lake City, UT, ³University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁴University of Utah, 10 N 1900 E, UT
Background/Purpose: Gout is the most common inflammatory arthritis. Despite widespread availability of effective therapies and management guidelines from ACR and EULAR, many gout patients remain…
Abstract Number: 1301 • ACR Convergence 2024
Assessment and Comparison of Long-term Skill Retention Following a Teledidactic Musculoskeletal Ultrasound Course for Medical Students– the TELMUS Follow-up Study
Ricarda Neubauer¹, Claus Juergen Bauer², Simon Petzinna², Pantelis Karakostas², Florian Recker³ and Valentin Sebastian Schäfer⁴, ¹University Hospital of Bonn, Bonn, Germany, Bonn, Germany, ²Clinic of Internal Medicine III, Department of Rheumatology, University Hospital of Bonn, Bonn, Germany, Bonn, Germany, ³Department for Gynecology and Obstetrics, University Hospital Bonn, Germany, Bonn, Germany, ⁴Clinic of Internal Medicine III, Department of Rheumatology, University Hospital of Bonn, Bonn, Germany, 53127 Bonn, Nordrhein-Westfalen, Germany
Background/Purpose: Teledidactic and peer-to-peer teaching are promising approaches to promote musculoskeletal ultrasound (MSUS) training locally and globally. Given the constraints in personnel and time, the…
Abstract Number: 1264 • ACR Convergence 2024
Improving Mental Health Care for Youth with Juvenile Dermatomyositis Through Integration of Mental Health Screening into Pediatric Rheumatology Clinic
Emily Datyner, Lisa Buckley, Brittany Nelson and Alaina Davis, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN
Background/Purpose: The negative impact of juvenile dermatomyositis (JDM) on emotional health is well-recognized. Barriers to appropriate mental health treatment include limited availability of providers and…
Abstract Number: 1343 • ACR Convergence 2024
Heightened Gout Risk in Patients with Rheumatoid Arthritis: A National Cohort Study
Seonyoung Kang¹, Yeonghee Eun², Kyungdo Han³, Jinhyung Jung⁴, Seulkee Lee⁵, Hoon-Suk Cha⁶, Hyungjin Kim⁷, Jaejoon Lee⁵ and Dong Wook Shin⁸, ¹Samsung Medical Center, Gangnam-gu, Seoul, South Korea, ²Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Jongno-gu, Seoul, Republic of Korea, ³Department of Statistics and Actuarial Science, Soongsil University, Seoul, Republic of Korea, ⁴Department of Medical Statistics, College of Medicine, Catholic University of Korea, Seoul, Republic of Korea, ⁵Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ⁶Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ⁷Department of Medical Humanities, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ⁸Department of Family Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul
Background/Purpose: Although gout is a prevalent disease, the coexistence of rheumatoid arthritis (RA) and gout has been considered unusual. Only several case reports describing the…
Abstract Number: 1342 • ACR Convergence 2024
Utility of Anti-Carbamylated Antibodies in Early Rheumatoid Arthritis in South Asian Population
chandhu aS¹, Josna Joseph¹, ABHILASHA ARVIND MANWATKAR² and John Mathew³, ¹CMC Vellore, Vellore, Tamil Nadu, India, ²christian medical college, vellore, Tamil Nadu, India, ³Christian Medical college , Vellore , India, Vellore, India
Background/Purpose: Rheumatoid Arthritis (RA) is an autoantibody mediated disease with deforming peripheral arthritis. Autoantibodies widely used are rheumatoid factor (RF) and anti-citrullinated peptide antibody (ACPA).…
Abstract Number: 1345 • ACR Convergence 2024
Long-term Changes in Coronary Calcium Score Levels Among Patients with Rheumatoid Arthritis: A Cohort Study
Cristina Corrales Selaya¹, Nuria Vegas Revenga², Carmen Secada Gómez³, Jose Antonio parra-Blanco⁴, Virginia Portilla-González⁴, Ricardo Blanco-Alonso⁵, Miguel Angel Gonzalez-Gay⁶, ivan Ferraz-Amaro⁷ and alfonso Corrales-Martínez⁸, ¹Rheumatology, Marques de Valdecilla University Hospital. IDIVAL, Santander, Cantabria, Spain, ²Hospital Galdakao- Usansolo, Galdakao, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ⁵Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, ⁶University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ⁷Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ⁸Hospital Universitario Marques de Valdecilla, Santander, Spain
Background/Purpose: Rheumatoid arthritis (RA) patients have an increased risk of subclinical cardiovascular (CV) disease and, consequently, a higher incidence of CV events, compared to the…
Abstract Number: 1266 • ACR Convergence 2024
Anti-Mitochondrial Antibodies Associate with Disease Activity and IFNα Expression in Childhood-onset Systemic Lupus Erythematosus
Marina Barguil Macedo¹, Javad Wahadat², Albin Bjoerk³, Sylvia Kamphuis², Marjan Versnel² and Christian Lood¹, ¹University of Washington, Seattle, WA, ²Erasmus University Medical Center, Rotterdam, Netherlands, ³Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Extracellular mitochondria may represent a source of antigenic burden in autoimmune disorders, such as in systemic lupus erythematosus (SLE), in which those organelles, released…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].